| New approaches to the treatment of canine demodicosis. | |
| | |
MedLine Citation:
|
PMID: 10563009 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Topical amitraz is the only approved treatment for CGD; however, it is not always effective or well tolerated. Extra-label use of amitraz, milbemycin oxime, ivermectin, and moxidectin may be effective therapeutical alternatives for dogs with resistant CGD or dogs that have an intolerance to the licensed amitraz protocol. It appears that oral administration of milbemycin oxime (1-2 mg/kg), ivermectin (400-600 micrograms/kg), and moxidectin (400 micrograms/kg) daily is a practical therapeutical alternative and would provide similar cure rates. Nevertheless, milbemycin oxime is expensive, ivermectin is potentially more toxic, and only limited information is available on moxidectin. The average treatment duration with these new regimens is 4 months, with an expected range of 3 to 10 months. Treatment should be administered daily for a minimum of 3 months and for at least 1 month after a series of negative skin scrapings. For chronic cases or cases that take a relatively long time to respond to therapy, 2 to 3 months of treatment beyond negative scrapings may be more appropriate. Dogs with CGD always approach clinical normalcy weeks to months before negative skin scrapings are obtained. All dogs respond at their own rate; as long as the skin scrapings at each visit show fewer mites, the current therapy should be continued for an additional month. If the mite count starts to increase, this may suggest that the treatment protocol is not being followed or it may be that the therapy chosen was suboptimally effective. Although CGD is still a disease that is not easily treated, the prognosis for dogs with this disorder has dramatically improved in the past few years. It must be remembered, however, that the treatment alternatives for CGD described above are not approved and should not be used unless the approved therapeutical regimen has failed. |
| | |
Authors:
|
M Paradis |
Related Documents
:
|
17300599 - Nonablative infrared skin tightening in type iv to v asian skin: a prospective clinical... 15577199 - Anthocyanin concentration of "assaria" pomegranate fruits during different cold storage... 16848819 - Evaluation of fluence and pulse-duration on purpuric threshold using an extended pulse ... 17455889 - Combining superficial glycolic acid (alpha-hydroxy acid) peels with microdermabrasion t... 20952869 - A study of peripheral t-lymphocytes in alopecia areata. 10886269 - Long-term evaluation of the long-pulsed alexandrite laser for the removal of bikini hai... 2819619 - Arterial reconstruction to the foot vessels: is it worth the trouble? 21519749 - Systemic inflammation and carotid diameter in obese patients: pilot comparative study w... 7025259 - Fenbufen as a single daily dose in the treatment of rheumatoid arthritis. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Veterinary clinics of North America. Small animal practice Volume: 29 ISSN: 0195-5616 ISO Abbreviation: Vet. Clin. North Am. Small Anim. Pract. Publication Date: 1999 Nov |
Date Detail:
|
Created Date: 1999-12-23 Completed Date: 1999-12-23 Revised Date: 2005-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7809942 Medline TA: Vet Clin North Am Small Anim Pract Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1425-36 Citation Subset: IM |
Affiliation:
|
Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montreal, St-Hyacinthe, Québec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Bacterial Agents / therapeutic use Antiparasitic Agents Dog Diseases / drug therapy*, prevention & control* Dogs Insect Repellents / therapeutic use* Insecticides / therapeutic use* Ivermectin / therapeutic use Macrolides Mite Infestations / drug therapy, prevention & control, veterinary* Prognosis Skin Diseases, Parasitic / prevention & control, veterinary* Toluidines / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Antiparasitic Agents; 0/Insect Repellents; 0/Insecticides; 0/Macrolides; 0/Toluidines; 129496-10-2/milbemycin oxime; 33089-61-1/amitraz; 51570-36-6/milbemycin; 70288-86-7/Ivermectin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Advances in flea control.
Next Document: Advances in the diagnosis and treatment of atopy.